IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma

作者：Qiulu Zhong, Xiaodong Zhu, Ling Li, Song Qu, Zhongguo Liang, Fanyan Zeng, Xin‐Bin Pan · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.14799 · 被引用次数：13 · 研究领域：Head and Neck Cancer Studies、Biological Research and Disease Studies、Cancer Research and Treatment

// Qiulu Zhong 1 , Xiaodong Zhu 1 , Ling Li 1 , Song Qu 1 , Zhongguo Liang 1 , Fanyan Zeng 1 and Xinbin Pan 1 1 Department of Radiation Oncology, The Affiliated Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China Correspondence to: Xiaodong Zhu, email: // Keywords : nasopharyngeal carcinoma; intensity-modulated radiotherapy; concurrent chemoradiotherapy; concurrent chemoradiotherapy plus adjuvant chemotherapy Received : August 15, 2016 Accepted : December 07, 2016 Published : January 23, 2017 Abstract Purpose: To evaluate the efficacy of IMRT combined with concurrent chemotherapy followed by adjuvant chemotherapy compared with IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma. Methods: From January 2007 to December 2014, we collected 797 staged II-IVb [UICC = Union for International Cancer Control criteria (7th edition)] NPC patients for analysis. After 1:1 matching ,we selected 261 cases as the CCRT group, another 261 patients as the CCRT+AC group. Using Kaplan-Meier to calculate the overall survival (OS), locoregional failure-free survival(LFFS), distant metastasis failure-free survival(DMFS). The log-rank test and Cox-proportional hazards model to evaluate the prognostic factors. Results: After matching, there were 261 patients in each group. In CCRT+AC group, The 1-,2- and 3- year os rates were a little higher than in CCRT group(99.6% vs 97.9%,97.4% vs 96.2%,9...